$19.76▾ 0.80%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
+91.8%year over year
Decelerating
Still growing fast, but the pace has been easing.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
✦ The read
Syndax Pharmaceuticals, Inc.'s earnings-quality signal is not available yet. Still growing fast, but the pace has been easing.
Key numbers
Valuation
EPS (TTM)$-2.52
TTM (trailing 12 months, through fiscal Q2 FY2026)
Profitability
Net margin-87.5%
TTM (trailing 12 months, through fiscal Q2 FY2026)
Size
Revenue (TTM)$252.25M
TTM (trailing 12 months, through fiscal Q2 FY2026)
Signals and key numbers are from the fiscal Q2 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.